

Obesity and the kidney

*Eberhard Ritz
Heidelberg (Germany)*



Obesity – *an ancient German tradition*



Conard, *Nature* (2009)460:737

0 1 cm

Venus vom “Hohlen Fels“

female figurine of mammoth ivory; 35,000 years B.C. (Aurignacien); Schelklingen (Württemberg)

The relation of “body mass index“
between **adoree** and **adorer**
has changed in the course of history

2000 v. Chr...



2000 n. Chr...



Obesity and the kidney



*Venus of
Willendorf
(Austria)
4000 BC*

- **Epidemiology of CKD and ESRD in obesity**
- **Renal morphology and function in obesity**
- **Role of visceral obesity**
- **Reversibility of renal pathology in obesity**
- **Renal consequences of bariatric surgery**
- **“Obesity” – always detrimental ?**
(“one body weight is optimal for all?”)

**Body mass index (BMI) at age 20 years –
important determinant of CKD risk at adult age**

Risk of advanced CKD (S-creatinine > 3.4 mg/dl)

Swedish country wide “case control” study

BMI (kg/m²)	odds ratio	
	Men	Women
< 25	1.0	1.0
> 25	3.1 (2.1-4.8)	3.0 (1.4-6.1)


Onset of reduced renal function → depends on **BMI**

- **Framingham study**,
1223 men, 1362 women, 43 years
- 1978-1982 vs 1998-2001
- *odds ratio : eGFR < 90 ml/min in the course of 10 years*
 - age OR 2.3
 - diabetes OR 2.6
 - smoking OR 1.42
 - **BMI OR 1.23 per 1 SD**

BMI

independent predictor of “endstage renal disease”

USA



Hsu, *Ann.Int.Med.*(2006) 144:21

BMI

independent predictor of “endstage renal disease”

Europe

Obesity and chronic kidney disease

894 576 participants, 61% male, age 46 ± 11 years


hazard ratio per 5 kg/m² higher BMI

15-25 kg/m²

25-50 kg/m²

Kidney Disease :


1.14 (0.74-1.77)



1.59 (1.27-1.99)

Diabetes :

0.96 (0.59-1.55)



2.16 (1.89-2.46)

Prospective Studies Collaboration, Lancet (2009) 373:1083

Risk of ESRD at obesity > 30kg/m²

higher in young as compared to elderly individuals


Risk underestimated in the elderly? Cardiovascular death competing risk!

age	Hazard ratio					
	BMI (kg/m ²)					
	<18.5	18.5-24.9	25.0-29.9	30.0-34.9	35.0-39.9	>40.0
< 40 years	0.2	1.0	1.8	4.4	7.3	11.6
> 40 years	0.8	1.0	1.9	3.1	5.5	4.8

Hsu, Ann.Int.Med.(2006) 144:21

BMI

independent predictor of “endstage renal disease” ($\text{♂} > \text{♀}$)
Japan



Iseki, Kidney Intern (2004) 65: 1870

Obesity and Oxidative Stress Predict AKI after Cardiac Surgery

Frederic T. Billings IV,^{*} Mias Pretorius,[†] Jonathan S. Schildcrout,[‡] Nathaniel D. Mercaldo,[‡] John G. Byrne,[§] T. Alp Ikizler,^{||} and Nancy J. Brown[¶]

JASN (2012) 23:1221

**not only chronic kidney disease,
but also acute kidney disease :**

“the relative risk of AKI increases significantly by 26.5% per 5 kg/m²
(*p*=0.02)
compared to individuals with normal body weight
(*BMI* 18-24.9 kg/m²) “

BMI : weaknesses

- based on “fat mass“ as well as “lean mass“ (*Sumo wrestlers*)
- does not consider distribution of fat tissue (*central vs peripheral*)

abdominal adiposity is associated with **CKD** –

independent of whether generalised adiposity is present or not

i.e. even isolated abdominal adiposity causes pathology

Kurella, J.Am.Soc.Nephrol.(2005) 16:2134

Lee, Am.J.Hypertens.(2007) 20:1189

does not reflect ectopic fat deposits in heart, vessels and kidney (sinus!)

in diabetic and nondiabetic individuals with CV disease

Montani, Int.J.Obes.Relat.Metab.Disord. (2004) 28(suppl 4)S58

Not all fat tissue is created equal : example

“brown adipose tissue“

- **inversely correlated with BMI**

Saito, Diabetes (2009) 58:1526

Cypess, New Engl.J.Med.(2009) 360:1509

- **thermogenesis (*high energy – consumption*)**

Lowell, Nature (2000) 404:652

- **expression of UCP1 (*uncoupling protein*)**

e.g. thermogenesis induced by cold or diet

van Marken, New Engl.J.Med.(2009) 360:1500

- **animal experiments: transplantation of “brown adipose tissue“ ameliorates obesity and metabolic syndrome**

Whittle, Trends Mol.Med.(2011) 17:405

Key abnormality : nonalcoholic fatty liver disease

Periphery:

- (inflammation)
- (insulin resistance of fat cells)
- increased lipolysis ⇨ causes infiltration of liver by free fatty acids

Liver:

Benign steatosis {

- diminished oxydation of fatty acids
- increased de novo lipogenesis (via hyperinsulinemia)
- disturbance of VLDL secretion

Malignant steatosis {

- lipid oxidation (ROS)
- gut : # bacterial endotoxin
short chain fatty acids
- adipokine imbalance

inflammation of visceral fat ⇨ insulin resistance

Stefan, Diabetes (2011) 60:2011

Hamad, Arab J.Gastroenterology (2012) 13:161

Plasma fetuin-A concentration and MI risk


(renal risk as well ?)

EPIC study



*Fat liver is the culprit of : increased **fetuin A** synthesis*

*Fetuin A inhibits insulin receptor-tyrosinkinase → **insulin resistance***

rel.risk
myokardial
infarction



Weikert, *Circulation* (2008) 118:2555




Unsavory ?

Transfer of **bacteria** from **colon** of slim donors into the **duodenum** of obese recipients with metabolic syndrome

colonisation by clostridium difficile :
 increase of peripheral and hepatic insulin sensitivity
 and
 increased butyrate synthesis in the gut

Vrieze, *Gastroenterology* (2012) 143:913



Another example of sequelae of gut bacteria

Obesity-induced *gut microbial metabolite* promotes liver cancer through senescence secretome

*Shin Yoshimoto, Tze Mun Loo, Koji Atarashi et al
Nature (2013)499:97*

“Fatty kidney sinus“

prediction of renal risk

(Framingham Heart Study)



	Fatty kidney sinus (n=879)	No fatty kidney sinus (n=2044)	p
Systolic BP (mmHg)	129 ± 17	120 ± 15	< 0.0001
Diastolic BP (mmHg)	75 ± 11	75 ± 9	< 0.0001
Hypertension (%)	57.8 %	26.6%	< 0.0001
Diabetes (%)	14.6 %	4.2%	< 0.0001
eGFR_{cystatin} (ml/min/1.73m ²)	81 ± 17	89 ± 16	< 0.0005
CKD	9.1%	2.8%	< 0.0005

Assessment of body fat in **men** (and women)

⇒ **“waist circumference”**


best predictor of percent body fat (and onset of type 2 diabetes)

(validated by magnetic resonance tomography)



6 year-incidence of **microalbuminuria** in non-diabetic individuals predicted by waist circumference

DESIR study



Bonnet, J.Hypertens.(2006)24:1157

Obesity and the kidney



*Venus of Willendorf
(Austria)
4000 BC*

- Epidemiology of CKD and ESRD in obesity
- **Renal morphology and function in obesity**
- Role of visceral obesity
- Reversibility of renal pathology in obesity
- Renal consequences of bariatric surgery
- **“Obesity” – always detrimental ?**
(*“one body weight is optimal for all?”*)

Kidney in Obesity

Ritz, Semin.Nephrol.(2009) 29:504

- # renal problems caused by non-parenchymal kidney disease
(renal carcinoma, nephrolithiasis)

Adams, Am.J.Epidemiol. (2008)168: 268

Obligado, Am.J.Hypertens.(2008) 21:257

- # one **specific form** of primary kidney disease induced by obesity
(focal segmental glomerulosclerosis FSGS)

Weisinger, Ann.Int.Med.(1974)81:440

Kambham, Kidn.Internat,(2001)59:1498

- # worsening of prognosis of **primary kidney diseases**
(uninephrectomy, IgA-GN, kidney-allograft, (pre)diabetic nephropathy ...)

Gonzales, Kidn.Internat.(2005)68:263



Bonnet,Am.J.Kidn.Dis.(2001)37:720

Meier-Kriesche, Transplantation (2002)73:704

Altiparmak, Netherl.J.Med.(2002)60:260


Risk amplifier : uninephrectomy

Proteinuria and **reduced renal function**
in patients after uninephrectomy → depending on BMI





Gonzales, *Kidn. Intern.* (2005) 68:263

“Obesity related
glomerulopathy”



Glomerulus :

hypertrophy
and
podocyte
pathology







Control

Obesity

*Chen,
AJKD (2006)48:772*


Individuals with extreme obesity may have major glomerular pathology ⇒ despite normal renal function




Nodular Glomerulosclerosis (!)

in a patient with metabolic syndrome **despite no diabetes**


Souraty, Nat.Clin.Pract.Nephrol.(2008) 4:639



PAS methenamine silver stain x400



*selective
capillary - BM
thickening
(570nm)*





*control without
thickening of
glomerul.BM
(Tungstic
acid stain)*

Not only glomerulus



Interstitial fibrosis;
tubular atrophy

Arterial wall sclerosis (arrow)

metabolic
syndrome




no
metabolic
syndrome



Alexander M. et al
Kidney pathological changes in metabolic syndrome
Am.J.Kidn.Dis.(2009) 53:751

Which biochemical mechanisms involved in obesity associated glomerulopathy ?

glomerular gene expression (microarray and real time PCR)
molecules of lipid metabolism, inflammation, insulin resistance



Obesity : renal sequelae

(summary)

- **Hemodynamics**

- *increased RPF, GFR, FF, albuminuria*

- **Structural changes**

- *increased kidney weight, higher glomerular-volume, mesangial expansion
podocyte damage*

- **Pathology**

- *glomerulomegaly, glomerulosclerosis, obesity-glomerulopathy*

- **Chronic kidney disease (CKD)**

- *proteinuria, increased risk of CKD, progression of CKD*

- **Terminal renal failure**

- *increased incidence and prevalence of renal failure, but better survival
on dialysis (!),*

- *increased risk of loss of kidney graft*


- **Further renal complications**

- *increased frequency of renal-cell carcinoma and of nephrolithiasis*

Eknoyan, Revista Nefrologia (2011) 31: 397

Metabolic syndrome

hyperfiltration even in **young** individuals




1572 healthy young males (mean age 18 years)

Risk of hyperfiltration (Cockcroft-Gault Ccr $>2SD$ above mean) → **6.9 fold increased**

Tomaszewski, *Kidn.Intern.*(2007) 71:816

Correlation between **BMI** and filtration fraction (**FF**) *presumably indicating glomerular hypertension*




Bosma, Kidn.Internat.(2004) 65:259


Patients with IgA-GN

(as one example of primary kidney disease)

Onset of **CKD** dependent on **BMI**



In individuals with advanced age
high BMI \Rightarrow glomerular reserve reduced (kidney donors)



glomerular reserve:
 Δ GFR after Dopamin

Estimation of GFR :

Obesity increases Cystatin C values independent of GFR

Cystatin C (*endogenous Cathepsin Protease Inhibitor*)

in obesity increased production by human adipocytes in vitro

Comparison :

237 individuals without obesity (age 51 years; BMI $22.8 \pm 0.11 \text{kg/m}^2$)

248 individuals with obesity (age 50 years; BMI $34.7 \pm 0.29 \text{kg/m}^2$)

Cystatin C serum concentration increased in obesity of both genders

– independent of GFR

fat tissue biopsies :

gene expression and secretion of Cystatin C increased

(subcutaneous and omentum fat)

Naour, Obesity (Silver Spring) (2009) 17:2121

Obesity and the kidney



*Venus of Willendorf
(Austria)
4000 BC*


- Epidemiology of CKD and ESRD in obesity
- Renal morphology and function in obesity
- **Role of visceral obesity**
- Reversibility of renal pathology in obesity
- Renal consequences of bariatric surgery
- **“Obesity” – always detrimental ?**
(*“one body weight is optimal for all?”*)



Waist circumference


♂ 102 cm, ♀ 88 cm

Android (apple) vs.gynoid (pear) obesity



A pioneer: Jean Vague, Marseille (1947)

Mortality (incl. carcinoma-mortality) **not** increased in obese individuals with **normal insulin sensitivity** (Cremona study)



not all obese are at risk , only the ones with insulin resistance

Visceral obesity and kidney function

(“normal weight obesity”)

even in individuals with **normal body mass index (BMI)**
central fat deposition (**waist-hip ratio**) is associated with
higher risk of :

microalbuminuria

RR 1.7 (1.19-3.12)

reduced eGFR

RR 1.9 (1.19-3.12) “lean”


2.0 (1.19-31.9) “overweight”

2.7 (1.46-4.85) “obese”

Pinto-Sietsma, Am.J.Kidn.Dis.(2003) 41: 733

The higher the “body mass index“ the more **albumin** excretion is amplified -
but this is **further amplified** by high **NaCl** intake
(Prevend study)

Albuminuria



The Paradox of Insulin-Resistance

- Insulin **sensitivity** is reduced in:

- ✓ *Muscle*
- ✓ *Fat tissue*
- ✓ *Liver*
- ✓ *...*

- but Insulin sensitivity is **not** reduced in :

the Kidney

→ ***increased sodium reabsorption***

Rocchini, Hypertension (1989) 14:367

the CNS

→ ***increased sympathetic-tone***

Landsberg, J.Hypertens. (2001) 19:523

Patients with **metabolic syndrome**

⇒ increased blood pressure response to **salt intake**

**Metabolic syndrome
components**

**Blood pressure-decrease
switch from 8.2 → 2.3 g NaCl/day**

4-5

- 8.7 ± 1.3 mmHg

3

- 6.0 ± 1.1 mmHg


< 3

0 mmHg

p < 0.0001

Hoffmann, J. Human Hypertens. (2007) 21:438

Why does sodium intake increase blood pressure preferentially in insulin resistance?



after Bakris,

- *antinatriuretic effect of insulin maintained*
- *vasodilatory NO mediated effects are cancelled*
- *RAS upregulated*

Adiposity

RAS

- activated

Gorzelniaak, J. Hypertens. (2002) 20:965

Aldosteron-secretion

- independent of classical stimuli aldosterone synthesis stimulated by a factor synthesized in visceral fat cells

*(adipocyte derived secretagogue EKODE, produced in visceral adipocytes)
Erhart-Bornstein, Proc.Natl.Acad.Sci USA (2003) 100:1421
Goodfriend Hypertension (2004) 43:358*

Aldosteron novel treatment target in visceral adiposity

- Factor produced in visceral fat cells stimulates aldosterone synthesis causing **aldosterone**-produced **podocyte-damage** (rat model of metabolic syndrome)

Nagase, J.Am.Soc.Nephrol.(2006) 17:3438

- **Eplerenone** → **reduction** of podocyte-damage and proteinuria

Nagase, Hypertension (2006) 47:1084

Obesity and the kidney




*Venus of
Willendorf
(Austria)
4000 BC*

- **Epidemiology of CKD and ESRD in obesity**
- **Renal morphology and function in obesity**
- **Role of visceral obesity**
- **Reversibility of renal pathology in obesity**
- **“Obesity” – always detrimental ?**
(“one body weight is optimal for all?”)


Weight loss and reduction of Proteinuria

(prospective controlled study)



intensified treatment

(weight loss)





routine treatment

Morales, Am.J.Kidn.Dis.(2003) 41:319

Weight reduction in morbid obesity → regression of **GFR**, **RPF** and **Albuminuria**

BMI 48±2.4 → 32.7±1.5 kg/m²



Albuminuria from 16 $\mu\text{g}/\text{min}$ (4-152) to 5 $\mu\text{g}/\text{min}$ (3-37)

Impact of body weight reduction on renal function in **CKD patients**

38 obese CKD patients

2 months; reduction of body weight >3%

s-creatinine	1,1±0.3	→ 0.8± 0.3	<i>p<.001</i>
eGFR	75.9±21.2	→ 104± 50.0	<i>p<0.001</i>
proteinuria	73%	→ 50.5%	<i>p=0.02</i>

Wang, J. Renal Nutrition (2013) e-pub Jun 2013)

Obesity and the kidney



*Venus of Willendorf
(Austria)
4000 BC*

- Epidemiology of CKD and ESRD in obesity
- Renal morphology and function in obesity
- Role of visceral obesity
- Reversibility of renal pathology in obesity
- **Renal consequences of bariatric surgery**
- **“Obesity” – always detrimental ?**
(*“one body weight is optimal for all?”*)

Bariatric surgery – stop and reversal of progression of CKD

25 patients CKD 3 (GFR 30-59 ml/min/1.73m²)

“morbid obesity“ (BMI 49.8 kg

GFR 47.9 ml/min/1.73m²)

1 year after surgery control :

body mass index :

from 49.8 to 34.5 kg/m²

systolic blood pressure :

from 133±13 mmHg to 128±17 mmHg

eGFR :

from 47.9 to 61.6 ml/Min/1.73m²

But no improvement of **survival** ?

*Retrospective Cohort study VA 2000 - 2006
850 Veterans compared to 41,244 non-operated controls
mean age 49,5 years, BMI 47,4 ± 7,8
6.7 years follow-up*

Non-adjusted Cox regression analysis :

reduction of mortality **HR 0.64 (CI 0.51 - 0.8)**

“Propensity matched” analysis


no significant reduction of mortality **HR 0.83 (CI 0.61 - 1.14)**

Maciejewski, JAMA (2011) 305: 2419

Bariatric Surgery : Prevention of Type 2 Diabetes

(SOS study [Swedish obese subjects])

15 years study, onset of type 2 diabetes in individuals with elevated basal-glycemia and basal insulin concentration



Obesity and the kidney




Venus of
Willendorf
(Austria)
4000 BC

- Epidemiology of CKD and ESRD in obesity
- Renal morphology and function in obesity
- Role of visceral obesity
- Reversibility of renal pathology in obesity

Obesity

- *not simply high body weight .*
- *the type of fat*
- *the distribution of fat deposits ...*
- **“Obesity” – always detrimental ?**
(*“is one body weight: optimal for all?”*)

Cardiovascular mortality is higher in meager individuals with hypertension (Tecumseh, Michigan)



Graph of age-adjusted 29-year cardiovascular disease (CVD) mortality by decile of Metropolitan relative weight and hypertension status.


Carman, Circulation (1994) 89:703

➡ meager individuals : more frequently hypertensive and higher reactivity of neuroendocrine systems (sympathetic and RAS systems)

Weber, Lancet (2013) 381:537


“Obesity paradox”

571 patients with *stable coronary heart disease*
highest event rate in underweight patients
best outcomes in overweight patients without obesity



BMI and “all-cause” mortality

Patients with acute *coronary syndrome* and/or significant *coronary heart disease*



Angerås, *Europ.Heart J.*(2013) 34:345

Obesity and Kidney



Venus von
Willendorf
4000 BC

- **Epidemiology** of obesity
- Epidemiology of **CKD** and **ESRD** in obesity
- **Renal morphology** and **function** in obesity
- The role of **visceral obesity**
- **Reversibility** of renal morphology and function in obesity
- Renal outcomes after **bariatric surgery**
- **“Obesity” – always detrimental ?**
(“one single weight is not optimal for all“)

**Thank you for
your attention**



prof.e.ritz@t-online.de

Obesity and the kidney



Venus of
Willendorf
(Austria)
4000 BC

- Epidemiology of CKD and ESRD in obesity
- Renal morphology and function in obesity
- Role of visceral obesity
- Reversibility of renal pathology in obesity


Obesity

- *not simply high body weight .*
- *the type of fat*
- *the distribution of fat deposits ...*

- **“Obesity” – always detrimental ?**
(*“is one body weight: optimal for all?”*)

**Even in the general population
the relative risk of eGFR loss depends on **waist-hip ratio****

PREVEND study (Groningen)



Pinto-Sietsma, Am.J.Kidn.Dis.(2003) 41: 733

Why increased salt sensitivity ?

Increased glomerular filtration in obesity :
⇒ **increased proximal tubular sodium reabsorption**

Study in 12 obese (BMI > 36) and 19 normal weight individuals :

GFR, RPF, FF

fractional excretion of lithium (*index of fractional proximal tubular Na reabsorption*)

6 of 12 obese individuals:



**increased GFR and FF,
higher postglomerular oncotic pressure,
increased tubular Na⁺ reabsorption,
(low Lithium clearance)
higher glomerular capillary pressure ?**


Chagnac, Nephrol.Dial.Transplant.(2008) 23:3946

Assessment of body fat in **women**

⇒ **“waist circumference”**


best predictor of percent body fat

(validated by magnetic resonance tomography)





Schulze, *Diabetologia* (2012) 55:1660


Prevalence of “chronic kidney disease“ (CKD)
(serum creatinine and Cystatin C)
relation to “fatty kidney sinus“ and visceral adiposity
(Framingham Heart Study)



Another culprit : cerebral insulin resistance
*insulin resistance favours increased
body weight and body fat (incl. fat in renal pelvis)
reversible by “lifestyle intervention“*
(Tübingen lifestyle study)




visceral fat



intrahepatic fat

Different severity of the metabolic syndrome and the resulting

prevalence of **CKD** (*chronic kidney disease*) and **microalbuminuria**




Kramer, Contrib.Nephrol.(2006) 151:1

Body mass index and **CKD**


Metaanalysis

Overweight BMI 25-30 kg/m²

Obesity BMI >30 kg/m²



↑
rel.Risk 1,4




↑
rel.Risk 1,9

Wang, *Kidn.Internat.*(2008) 73:19


Metabolic syndrome : risk factor for

CKD (*chronic kidney disease*) and **microalbuminuria**

Prevalence of **CKD**
(%)



Prevalence of **microalbuminuria**
(%)



**metabolic
syndrome**

waist circumference:

>102cm (men)

fasting glucose:

>110mg/dl

HDL-C:

<40mg/dl

triglycerides:

>140mg/dl

blood pressure:

>130/80mmHg

**Risk (*odds ratio*) of onset of CKD
in individuals with 1 or more components
of the metabolic syndrome**

Blood pressure >130/85mm	2.04	<0,001
S-triglycerides >159mg/dl	1.92	”
Plasma-glucose >110mg/dl	1.68	”
S-HDL cholesterol < 40mg/dl	1.63	”
Waist circumference >90cm♂ 80cm♀	1.32	”


Number of components of metabolic syndrome and renal risk

1 component	1.46	not significant
2 components	1.63	dto
3 components	2.75	dto
4 components	3.56	< 0.001
5 components	4.47	< 0.001

Overweight and Obesity – “Paradox“

with increasing BMI :


*better survival. less frequent recurrent stroke and better preservation of function
(TEMPIS trial)*




Doehner, Europ Heart J. (2012) 34:268

Link between Obesity and ESRD :

*ESRD only the consequence of diabetes and hypertension –
or is obesity directly injuring the kidney ?*



In extreme obesity correlation body weight and mean glomerular area



Goumenos, *Nephrol.Dial.Transplant.*(2009) 24: 3732

High waist-hip-ratio (WHR) impacts on renal hemodynamics

*315 healthy persons, BMI 24.9 kg/m²
GFR ¹²⁵I-iothalamate 109 ml/min/1.73m²
renal parameters adjusted for BSA*

WHR inversely correlated with:

GFR $r = -0.201; p < 0.001$ - lower GFR

ERPF $r = -0.431; p < 0.001$ - lower GFR

positive correlation with:

FF $r = 0.357; p < 0.001$ - higher filtration fraction

Kwakernaak, J.Am.Soc.Nephrol.(2013) 25:987

Central obesity and renal risk in type 1 diabetes

"waist circumference" predicts onset of microalbuminuria

